NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe’s mission is to identify and address the needs of patients that are insufficiently met by current treatments. NuPathe’s product portfolio includes Zelrix which, if approved, would be the first and only transdermal patch for the treatment of acute migraine, and NP201, a long acting injectable implant for the treatment of Parkinson’s disease.
Zelrix is a novel transdermal patch in phase III clinical development for acute migraine. Today, only 50 percent of migraine patients are satisfied with their migraine treatment due to issues such as migraine-related nausea/vomiting, inconsistent relief, and side-effects. Zelrix was conceived and designed to address these issues and provide patients with improved ability to take control over their migraine.
Website:
www.nupathe.com
Safeguard Partner Company since 2006
